Latest ArticlesGene therapy provides a new treatment method for malignant tumors, genetic diseases and rare diseases. However, there are many barriers in the process of in vivo gene delivery, which limit the clinical application of gene therapy. It is urgently needed to develop suitable carriers for encapsulating, delivering and protecting gene. As a lipid bilayer membrane vesicle actively secreted by living cells(including tumor cells, platelets, antigen presenting cells), exosomes have many advantages, such as natural activity, high biocompatibility, low immunogenicity, and low toxicity, which are considered to be one of the most potential gene delivery carriers. Based on the advantages of exosomes, this paper reviews the isolation of exosomes, gene loading methods and transformation strategies of exosomes, which provides a reference for exosomes as a carrier in the field of gene therapy.
mRNA vaccines have attracted extensive attention from academia, industry, and regulatory agencies for their development flexibility and high immunogenicity. They have been widely used to prevent and control the Corona Virus Disease 2019(COVID-19). While mRNA vaccines have a low risk of recombination and good safety, their poor stability and strict storage and transportation conditions limit their applications. Nucleic acid modifications and novel delivery systems have been used to improve the stability of mRNA vaccines and enhance their safety and efficacy. From the perspective of the molecular basis and formulation development of mRNA vaccines, the development status and critical technologies of mRNA vaccines are reviewed, and the challenges and possible solutions of mRNA vaccines in the development and application are discussed.
Traditional microspheres loaded with protein/polypeptide drugs have some shortcomings, such as burst release, delayed release, and incomplete release of protein/peptide drugs. However, microspheres with poly(lactide-co-glycolide)(PLGA) as carriers can achieve sustained release delivery of protein/polypeptide drugs and improve patient compliance. This paper analyzes the various factors that affect drug release performance of microspheres, and summarizes a variety of improvement strategies from the aspects of carrier materials and preparation technology, especially the remolding methods on the internal water phase in the emulsion-solvent evaporation method. Besides, the application of new technology, such as microfluidic, supercritical fluid, self-healing encapsulation, and the development of core-shell microspheres controlled-release drug delivery systems are also introduced to provide new ideas for the preparation of protein/polypeptide microspheres.
The industrialization of drugs often involves some dangerous chemical reaction steps, which affect the feasibility of large-scale industrial preparation in terms of environment, health and safety. Microreactor is a new type of reactor, compared with the traditional tank reactor, it has a more efficient mass and heat transfer effects, and higher safety performance. This paper reviews the characteristics and advantages of microreactor, summarizes the application of micro-reaction technology in the large-scale preparation, such as nitration, diazotization, chlorination, oxidation, hydrogenation, cyclization, and discusses its prospects of development of industrial applications.
4,4-Difluoro-boradiazaindacene dyes, BODIPY dyes, as traditional small organic molecule dyes, have been of significant interest due to their easy modifiable structures and tunable photophysical properties. The rationally designed BODIPYs could self-assemble into nanoparticles for tumor imaging and phototherapy in many approaches. Initially, different strategies for the construction of BODIPY nanoparticles are introduced in this review. Subsequently, the research progress of BODIPY nanoparticles in tumor fluorescence imaging, photoacoustic imaging, photodynamic therapy, photothermal therapy and combined photodynamic and photothermal therapy are summarized systematically. Finally, the future directions of BODIPY nanoparticles are prospected.
Suitable pharmaceutical packaging materials can provide safety, protection, functionality, convenience and other properties of drugs. The high popularity of high-tech pharmaceutical researches(innovative drugs, biological drugs, etc.), increasingly popular green environmental protection concept, and constantly developing technologies(biology, material science, electronic informatics, etc.), have put forward new demands for pharmaceutical packaging materials, thus promoting the rapid development of pharmaceutical packaging industry. On the basis of meeting the basic safety and protection requirements, pharmaceutical packaging materials also need to meet the higher requirements such as environmental protection, intelligence and convenience. In this paper, the research trend of pharmaceutical packaging materials in recent years is briefly reviewed from four perspectives, including green packaging, safe packaging, intelligent packaging and standard for packaging materials, which is expected to provide some references for the improvement and innovative research of pharmaceutical packaging materials.
1-(2,3-Dichlorophenyl)-4-[4-(3-nitrophenoxy)butyl]piperazine(5a) or 1-(benzo[b]thiophenyl)-4-[4-(3-nitrophenoxy)butyl]piperazine(5b) were prepared from 3-nitrophenol by etherification, and then N-alkylation reaction with 1-(2,3-dichlorophenyl)piperazine hydrochloride or 1-(benzo[b]thiophenyl)piperazine hydrochloride. The intermediate of aripiprazole or brexpiprazole, 1-(2,3-dichlorophenyl)-4-[4-(3-aminophenoxy)butyl]piperazine(3a) or 1-(benzo[b]thiophenyl)-4-[4-(3-aminophenoxy)butyl]piperazine(3b) were prepared by electroreduction reactions of 5a or 5b with yields of 93% and 97%, respectively.
In order to control the quality of roxadustat, six related substances of roxadustat were prepared: methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(related substance A), N-(4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)glycine(related substance B), methyl N-(4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)glycinate(related substance C), 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid(related substance D), methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate(related substance E), methyl N-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycinate(related substance F), and their structures were confirmed by mass spectrometry(MS) and nuclear magnetic resonance(NMR).
Protein L is a kind of cell wall-anchored surface proteins produced by Peptostreptococcus magnus, which can specifically bind to antibodies with the kappa light chain. Moreover, it is one of the crucial tools for antibody fragment purification. There are few types of Protein L affinity chromatographic packings for sale, and most of them are expensive. Meanwhile, the alkali resistance and capacity of the existing Protein L affinity chromatographic packings still need to be improved. In this study, the Protein L was expressed by high-density fermentation of constructing alkali-resistant mutant Protein L expression strain DMR582. After extraction with polyethylenimine(PEI), pretreatment and one-step cation exchange chromatography, the purity of Protein L reached 96.7%. Then, the purified Protein L fillers was immobilized on epoxy activated agarose medium to prepare Protein L affinity chromatographic medium. After parameter optimization, the dynamic binding capacity at 10% breakthrough(DBC10%) could reach 35 mg/mL for Fab. After 50 times of clean in place(CIP) with 100 mmol/L sodium hydroxide solution, the remaining DBC10% was 73.9%, higher than the ligand fillers with the original sequence. And after 100 times of CIP with 15 mmol/L sodium hydroxide solution, the remaining DBC10% could still maintain at 89.6% of the initial load, which was equivalent to the alkali resistance of Capto L resin.